The drug is administered by monthly intravenous infusions. An infusion takes about an hour. An alternative formulation for subcutaneous injection was approved in October 2013. Rheumatoid arthritis<unk>  is used for the treatment of moderate to severe rheumatoid arthritis, applied in combination with methotrexate, if other drugs like disease-modifying antirheumatic drugs (DMARDs) and TNF alpha blockers have proven to be ineffective or were not tolerated. It can be used as a monotherapy for patients who do not tolerate methotrexate. The drug slows down the progression of the disease and can improve physical function of patients. Systemic juvenile idiopathic arthritis The treatment of systemic juvenile idiopathic arthritis (SJIA) is similar to rheumatoid arthritis treatment:<unk>  is combined with methotrexate unless the latter is not tolerated. General safety and effectiveness is established for children of two years and older. In 2011, the U.S. Food and Drug Administration (U.S. FDA) approved<unk>  for the treatment of active systemic juvenile idiopathic arthritis. Castleman's disease In Japan,<unk>  is also approved for the treatment of Castleman's disease, a rare benign tumor of B cells. Giant cell arteritis In May 2017, the FDA approved<unk>  for giant cell (temporal) arteritis. Cytokine release syndrome On 30 August 2017, the FDA approved<unk>  for cytokine release syndrome, a side effect of CAR-T cell therapies. COVID-19 In June 2021, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for<unk>  for the treatment of COVID-19 in hospitalized people aged two years of age and older who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). In September 2021, Indian pharmaceutical firm Hetero obtained emergency use approval from the country's health authority, Drugs Controller General of India (DCGI), to produce a generic version of Roche's drug<unk>  to treat COVID-19 in adults. With the approval, the drug will be made available for treating hospitalised adults who are on systemic corticosteroids and need supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal oxygenation. A 2021 meta-analysis of randomized controlled trials found that, while<unk>  does not show significant benefits on survival, it could play a role in preventing progression to intensive care and mechanical ventilation. On 1 December 2021,<unk>  was granted a provisional approval by the Australian regulator, Therapeutic Goods Administration, for treatment of adults who are hospitalised with COVID-19, are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.
Tocilizumab
Satralizumab
Brolucizumab
Ixekizumab
Caplacizumab
Atezolizumab
Reslizumab
Risankizumab